drug discovery

The analytics firm formerly known as Quintiles IMS will offer researchers secure access to Genomics England's de-identified databases in pursuit of precision medicine.

The financing round will support uBiome's ongoing efforts to commercialize its clinical microbiome analysis, sexually-transmitted disease, and gut wellness tests.

Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.

Elucidata, which makes software to support drug discovery, recently released a metabolomics analysis platform that includes machine learning technology.

The UK-based Dementia Discovery Fund is investing $1.3M in Immuneering's drug-discovery technology in search of new molecular entities for treating Alzheimer's.

Genome-wide association study hits can uncover potential therapies for conditions like inflammatory bowel disease, a Biology of Genomes speaker said.

With the Series B funding, Sytenkabio will consolidate its headquarters in Seoul, validate its technology, and look to expand into international markets.

Envisagenics, which was spun out of Cold Spring Harbor Laboratory, has developed a platform to help drug companies address RNA splicing errors.